BioSpace News Archive

Glaukos Corporation plans to release third quarter 2023 financial results after the market close on Wednesday, November 1, 2023.

Gritstone bio, Inc. today announced the presentation of results from three ongoing Phase 1 studies evaluating its self-amplifying mRNA (samRNA) vaccine candidates against COVID-19 (part of the company’s CORAL program) at IDWeek 2023, occurring October 11-15, 2023, in Boston, MA.

BridgeBio Pharma, Inc. today announced that on October 06, 2023, the compensation committee of BridgeBio’s board of directors granted nineteen new employees restricted stock units for an aggregate of 227,507 shares of the Company’s common stock.

Coeptis Therapeutics Holdings, Inc. today announced that it has expanded its exclusive license agreement with the University of Pittsburgh to include the SNAP-CAR technology platform in natural killer (NK) cells.

ImmPACT Bio USA , Inc. today announced that it will participate at the BIO Investor Forum, to be held from October 17-18, 2023 in San Francisco, CA.

IQVIA, a leading global provider of advanced analytics, technology solutions, and clinical research services, and The Coalition for Epidemic Preparedness Innovations announced a strategic collaboration to advance the 100 Days Mission.

Perimeter Medical Imaging AI, Inc. announced that patient randomization is underway at Mayo Clinic in Florida, the most recent clinical site to be initiated as part of an ongoing multi-center, randomized two-arm pivotal clinical trial evaluating the investigational Perimeter B-Series OCT combined with its proprietary ImgAssist AI software.

Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) to treat cardiometabolic diseases, today announced top-line findings from a recent subgroup analysis of AspyreRx (formerly BT-001) in its pivotal trial for type 2 diabetes (T2D).

Apnimed, Inc. announced today the company will be participating in the following investor conferences in October 2023.

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that eight abstracts highlighting new data from its chronic hepatitis B (CHB) and chronic hepatitis delta (CHD) clinical programs have been accepted for presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting ® , taking place in Boston, MA, from November 10-14, 2023.